Almost one in four patients with advanced lung cancer in Europe, Asia and the US are not receiving appropriate testing for mutations in the EGFR gene, potentially leading to suboptimal outcomes. This is the conclusion of a report presented at the at the European Lung Cancer Conference (ELCC) being held in in Geneva, Switzerland.
Medical Oncologist James Spicer from King's College London at Guy's Hospital, London, and colleagues studied how widely hospitals had implemented…Continue
Added by Editorial Team on April 17, 2015 at 2:00pm — No Comments
The prevalence of childhood cancer survivors is estimated to have increased, and the majority of those who have survived five or more years beyond diagnosis may have at least one chronic health condition, according to a study funded by the National Institutes of Health and conducted in by collaborator in Northwestern University, the NCI, and St. Jude Children’s Research Hospital…Continue
Added by Editorial Team on April 17, 2015 at 10:30am — No Comments
An estimated 30% of patients with estrogen receptor α (ERα)-positive breast cancer being treated with the antiestrogen tamoxifen will either not respond to initial therapy or will develop drug resistance. A new study showed that the presence of lower-than-normal amounts of the protein TGFBR2 was associated with breast cancer resistance to treatment with the anti-estrogen therapeutic tamoxifen, according to a study funded by the Swedish Cancer Society, Breakthrough Breast Cancer…Continue
Added by Editorial Team on April 15, 2015 at 11:30am — No Comments
According to phase I clinical trial data published in Clinical Cancer Research, a journal published by American Association for Cancer Research (AACR), a new bispecific ligand-directed diphtheria toxin called DT2219 was found to be safe and clinically effective in a small group of patients with relapsed/refractory B-cell malignancies.
In this phase I trial, supported by the National Institutes of Health, the Randy Shaver Foundation, the Lions Children’s Cancer Fund, and…Continue
Added by Editorial Team on April 10, 2015 at 1:30pm — No Comments
Antibody–drug conjugates or ADCs are a burgeoning class of targeted therapies designed to deliver dual therapies in a single, cancer cell-killing package. Targeted therapies are unique in that they have the ability to attack cancer cells while leaving the surrounding, healthy cells, alone. This strategy is expected to result in more effective treatments for cancer - and potentially for other diseases - with fewer toxic side effects than traditional chemotherapies. 
Added by Editorial Team on April 7, 2015 at 6:30pm — No Comments
A drug used for decades to treat leukemia may have other uses in the fight against cancer, researchers at the University of Missouri have found. Previously, doctors used 6-Thioguanine, also known as 6-TG, a synthetic guanosine analogue antimetabolite being used as a chemotherapy treatment to kill cancer cells in patients with leukemia.
Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA,…Continue
Added by Editorial Team on April 1, 2015 at 10:00am — No Comments